Differential effect of LPS and paclitaxel on microglial functional phenotypes and circulating cytokines: the possible role of CX3CR1 and IL-4/10 in blocking persistent inflammation

  • Joong-Won Ha
  • Min-Jung You
  • Hyun-Sun Park
  • Jong Wan KimEmail author
  • Min-Soo KwonEmail author
Research Article


Neuroinflammation plays a role in cancer chemotherapy-induced chronic pain. Thus far, most studies have focused on neuroinflammation suppression. However, there are limited reports of which factor is involved in the transition from acute inflammation to chronic inflammation, resulting in neuroinflammation and chronic pain. Here, we compared the inflammatory reaction and pain response induced by LPS and paclitaxel. LPS (0.5 mg/kg) or paclitaxel (2 mg/kg/day for 5 days) was administered intraperitoneally to mice, and mechanical allodynia was examined by von Frey test. LPS induced transient mechanical allodynia, whereas paclitaxel induced persistent mechanical allodynia. The CD86/CX3CR1 ratio remained unchanged due to CX3CR1 elevation following LPS injection, whereas the ratio was increased on day 1 after paclitaxel injection. LPS also increased CD45, CCL2, and CCL5 mRNA in the spinal cord and circulating pro- and anti-inflammatory cytokines 1 day after injection; however, the pattern was not consistent. Paclitaxel gradually increased inflammatory cytokines in the spinal cord. CX3CR1 might be involved in blocking the transition from acute pain to persistent pain in the LPS group. In addition, serum IL-4 and IL-10 elevation in the LPS group may be associated with chronic pain prevention. Therefore, targeting CX3CR1, IL-4, and IL-10 might be an alternative therapeutic strategy.


Neuroinflammation LPS Paclitaxel Chronic pain Microglia Cytokines 



The authors would like to thank Han A for constructive criticism. This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2017R1C1B5018178).

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.


  1. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM (2006) Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9:917–924CrossRefGoogle Scholar
  2. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55–63CrossRefGoogle Scholar
  3. Corona AW, Norden DM, Skendelas JP, Huang Y, O’connor JC, Lawson M, Dantzer R, Kelley KW, Godbout JP (2013) Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice. Brain Behav Immun 31:134–142CrossRefGoogle Scholar
  4. Cronk JC, Filiano AJ, Louveau A, Marin I, Marsh R, Ji E, Goldman DH, Smirnov I, Geraci N, Acton S, Overall CC, Kipnis J (2018) Peripherally derived macrophages can engraft the brain independent of irradiation and maintain an identity distinct from microglia. J Exp Med 215:1627CrossRefGoogle Scholar
  5. Eijkelkamp N, Steen-Louws C, Hartgring SA, Willemen HL, Prado J, Lafeber FP, Heijnen CJ, Hack CE, Van Roon JA, Kavelaars A (2016) IL4-10 fusion protein is a novel drug to treat persistent inflammatory pain. J Neurosci 36:7353–7363CrossRefGoogle Scholar
  6. Geissmann F, Auffray C, Palframan R, Wirrig C, Ciocca A, Campisi L, Narni-Mancinelli E, Lauvau G (2008) Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol Cell Biol 86:398–408CrossRefGoogle Scholar
  7. Grace PM, Hutchinson MR, Maier SF, Watkins LR (2014) Pathological pain and the neuroimmune interface. Nat Rev Immunol 14:217–231CrossRefGoogle Scholar
  8. Gu N, Eyo UB, Murugan M, Peng J, Matta S, Dong H, Wu LJ (2016) Microglial P2Y12 receptors regulate microglial activation and surveillance during neuropathic pain. Brain Behav Immun 55:82–92CrossRefGoogle Scholar
  9. Guo LH, Schluesener HJ (2006) Acute but not chronic stimulation of glial cells in rat spinal cord by systemic injection of lipopolysaccharide is associated with hyperalgesia. Acta Neuropathol 112:703–713CrossRefGoogle Scholar
  10. Han A, Yeo H, Park MJ, Kim SH, Choi HJ, Hong CW, Kwon MS (2015) IL-4/10 prevents stress vulnerability following imipramine discontinuation. J Neuroinflammation 12:197CrossRefGoogle Scholar
  11. Hsieh CT, Lee YJ, Dai X, Ojeda NB, Lee HJ, Tien LT, Fan LW (2018) Systemic lipopolysaccharide-induced pain sensitivity and spinal inflammation were reduced by minocycline in neonatal rats. Int J Mol Sci. 4:5. Google Scholar
  12. Jaggi AS, Singh N (2012) Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 291:1–9CrossRefGoogle Scholar
  13. Ji RR, Xu ZZ, Gao YJ (2014) Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov 13:533–548CrossRefGoogle Scholar
  14. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH (2010) The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain 11:1230–1239CrossRefGoogle Scholar
  15. Kawasaki Y, Zhang L, Cheng JK, Ji RR (2008) Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci 28:5189–5194CrossRefGoogle Scholar
  16. Kipnis J (2018) Immune system: the “seventh sense”. J Exp Med 215:397–398CrossRefGoogle Scholar
  17. Kuner R (2010) Central mechanisms of pathological pain. Nat Med 16:1258–1266CrossRefGoogle Scholar
  18. Kwilasz AJ, Grace PM, Serbedzija P, Maier SF, Watkins LR (2015) The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology 96:55–69CrossRefGoogle Scholar
  19. Kwon MS, Seo YJ, Choi SM, Won MH, Lee JK, Park SH, Jung JS, Sim YB, Suh HW (2010) The time-dependent effect of lipopolysaccharide on kainic acid-induced neuronal death in hippocampal CA3 region: possible involvement of cytokines via glucocorticoid. Neuroscience 165:1333–1344CrossRefGoogle Scholar
  20. Li Y, Zhang H, Zhang H, Kosturakis AK, Jawad AB, Dougherty PM (2014) Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy. J Pain 15:712–725CrossRefGoogle Scholar
  21. Li D, Huang ZZ, Ling YZ, Wei JY, Cui Y, Zhang XZ, Zhu HQ, Xin WJ (2015) Up-regulation of CX3CL1 via nuclear factor-kappaB-dependent histone acetylation is involved in paclitaxel-induced peripheral neuropathy. Anesthesiology 122:1142–1151CrossRefGoogle Scholar
  22. Limatola C, Ransohoff RM (2014) Modulating neurotoxicity through CX3CL1/CX3CR1 signaling. Front Cell Neurosci 8:229CrossRefGoogle Scholar
  23. Liu CC, Lu N, Cui Y, Yang T, Zhao ZQ, Xin WJ, Liu XG (2010) Prevention of paclitaxel-induced allodynia by minocycline: effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. Mol Pain 6:76CrossRefGoogle Scholar
  24. Milligan E, Zapata V, Schoeniger D, Chacur M, Green P, Poole S, Martin D, Maier SF, Watkins LR (2005a) An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine. Eur J Neurosci 22:2775–2782CrossRefGoogle Scholar
  25. Milligan ED, Langer SJ, Sloane EM, He L, Wieseler-Frank J, O’connor K, Martin D, Forsayeth JR, Maier SF, Johnson K, Chavez RA, Leinwand LA, Watkins LR (2005b) Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci 21:2136–2148CrossRefGoogle Scholar
  26. Montague K, Simeoli R, Valente J, Malcangio M (2018) A novel interaction between CX3CR1 and CCR2 signalling in monocytes constitutes an underlying mechanism for persistent vincristine-induced pain. J Neuroinflammation 15:101CrossRefGoogle Scholar
  27. Noh MY, Lim SM, Oh KW, Cho KA, Park J, Kim KS, Lee SJ, Kwon MS, Kim SH (2016) Mesenchymal stem cells modulate the functional properties of microglia via TGF-beta secretion. Stem Cells Transl Med 5:1538–1549CrossRefGoogle Scholar
  28. Old EA, Nadkarni S, Grist J, Gentry C, Bevan S, Kim KW, Mogg AJ, Perretti M, Malcangio M (2014) Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain. J Clin Invest 124:2023–2036CrossRefGoogle Scholar
  29. Peng J, Gu N, Zhou L, Eyo UB, Murugan M, Gan WB, Wu LJ (2016) Microglia and monocytes synergistically promote the transition from acute to chronic pain after nerve injury. Nat Commun 7:12029CrossRefGoogle Scholar
  30. Pepe G, Calderazzi G, De Maglie M, Villa AM, Vegeto E (2014) Heterogeneous induction of microglia M2a phenotype by central administration of interleukin-4. J Neuroinflammation 11:211CrossRefGoogle Scholar
  31. Saijo K, Glass CK (2011) Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 11:775–787CrossRefGoogle Scholar
  32. Tsuda M, Inoue K, Salter MW (2005) Neuropathic pain and spinal microglia: a big problem from molecules in “small” glia. Trends Neurosci 28:101–107CrossRefGoogle Scholar
  33. Yoon SY, Patel D, Dougherty PM (2012) Minocycline blocks lipopolysaccharide induced hyperalgesia by suppression of microglia but not astrocytes. Neuroscience 221:214–224CrossRefGoogle Scholar
  34. Zhang H, Yoon SY, Zhang H, Dougherty PM (2012) Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. J Pain 13:293–303CrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2019

Authors and Affiliations

  1. 1.Department of Pharmacology, School of MedicineCHA UniversitySeongnam-siRepublic of Korea
  2. 2.Department of Orthopedic SurgeryNational Health Insurance Service Ilsan HospitalIlsanRepublic of Korea
  3. 3.Department of Surgery, Dongtan Sacred Heart HospitalHallym University College of MedicineHwaseong-SiRepublic of Korea

Personalised recommendations